26 search results for: disease background

expert video

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

10 min

Dermatology

In this ADVENT symposium at the 2024 EADV meeting, Professor Joost Meijer highlights the heterogeneous nature of BP and the resultant burden for patients.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

2 min

Dermatology

Dr. Elmariah introduces the multiple roles of type 2 cytokines in chronic itch.

expert video

Etiology and Diagnosis of Bullous Pemphigoid

2 min

Dermatology

Professor Joost Meijer discusses the complex etiology and diagnosis of BP

interactivity

Diagnosis of Bullous Pemphigoid Interactive Patient Case

10 min

Dermatology

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP)

interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

15 min

Dermatology

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

expert video

Type 2 Inflammation Contributes to Itch and Fibrois in PN

4 min

Dermatology

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid

Infographic

Bullous Pemphigoid (BP) Pathophysiology Infographic

4 min

Dermatology

A static infographic detailing how autoimmunity and Type 2 inflammation play a critical role in the pathophysiology of Bullous Pemphigoid (BP).

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: CanadaChange country/region